SBFM FY 2023 Earnings — Sunshine Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

SBFMSunshine Biopharma, Inc.

$6M

FY 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$24M+454.4% YoY

Gross Profit

$8M34.6% margin

Operating Income

-$5M-19.9% margin

Net Income

-$5M-18.7% margin

EPS (Diluted)

$-351.36

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$10M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$27M

Total Liabilities

$6M

Stockholders' Equity

$21M

Cash & Equivalents

$16M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$24M	$4M	+454.4%
Gross Profit	$8M	$2M	+391.4%
Operating Income	-$5M	-$27M	+82.3%
Net Income	-$5M	-$27M	+83.2%